IMMUNO-COV™ – The Test for Antibodies that Block SARS-CoV-2 Infection Read More

News Releases

May 9, 2021

How Safe are Staff and Patients in a Vaccinated World?

February 23, 2021

Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies

December 1, 2020

Vyriad Expands Clinical Study of Oncolytic Virus Therapy in Bladder Cancer Patients

November 19, 2020

Imanis Life Sciences Announces Improvements and Increased Capacity of IMMUNO-COV™️, a First-in-Class Neutralizing Antibody Test for COVID-19

September 14, 2020

Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium

July 20, 2020

Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications

June 11, 2020

Mayo Clinic to Offer Vyriad Neutralizing Antibody Test

May 29, 2020

Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting

May 28, 2020

Scientific Paper Available on Development and Validation of IMMUNO-COV™, Vyriad’s SARS-CoV-2 Virus-Neutralizing Antibody Test

May 12, 2020

Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19

April 28, 2020

Vyriad Oncolytic Measles Virus Therapy Enhances T-cell Responses in Multiple Myeloma Patients

December 11, 2019

Vyriad Inc. Names Experienced Life Sciences Investors Edwin Kania and Nathan Stacy to its Board of Directors

November 6, 2019

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

July 28, 2018

Vyriad Announces Collaboration with Merck KGaA and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer

May 10, 2018

Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.

August 15, 2017

Clinical trial uses a genetically engineered virus to fight cancer

April 25, 2017

Tessa Therapeutics and Vyriad Form Partnership to Create Next Generation of Cancer Immunotherapy Treatments

August 16, 2016

Vyriad Announces Agreement with Imanis Life Sciences for Development of Theranostic Tests to Predict Responsiveness to Oncolytic Virotherapy

August 5, 2016

Vyriad Appoints Alice Bexon, MD, as Chief Medical Officer

August 5, 2016

Vyriad Signs Exclusive License Agreement for STING Technology for Development of Enhanced Oncolytic Virotherapy Treatments

March 18, 2016

Omnis Pharma and Magnis Therapeutics Merge to Form Vyriad, a Clinical-Stage Oncolytic Immunovirotherapy Development Company

March 18, 2016

Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy